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Background: Equine laminitis is a devastating disease that causes severe pain in afflicted horses and places a major
economic burden on the horse industry. In acute laminitis, the disintegration of the dermal-epidermal junction can
cause the third phalanx to detach from the hoof wall, leaving the horse unable to bear weight on the affected
limbs. Horses that survive the acute phase transition into a chronic form of laminitis, which is often termed
“founder”. Some evidence suggests that chronic laminar inflammation might be associated with alterations in the
endocrine and immune systems. We investigated this broad hypothesis by using DIGE to assess global differences
in the plasma proteome between horses with chronic laminitis and controls.
Results: We identified 16 differentially expressed proteins; the majority of these were involved in the interrelated
coagulation, clotting, and kininogen cascades. Clinical testing of functional coagulation parameters in foundered
horses revealed a slight delay in prothrombin (PT) clotting time, although most other indices were within normal
ranges. Upregulation of the intestinal apolipoprotein APOA-IV in horses with chronic laminitis was confirmed by
western blot.
Conclusions: Our results support the hypothesis that localized laminar inflammation may be linked to systemic
alterations in immune regulation, particularly in the gastrointestinal system. Gastrointestinal inflammation has been
implicated in the development of acute laminitis but has not previously been associated with chronic laminitis.Background
Laminitis is a painful and debilitating disease of the
equine foot. The specific molecular factors initiating
laminitis are unknown, but it is often associated with in-
sulin resistance and obesity and can be precipitated by
diseases such as colic and diarrhea [1,2]. The acute
phase of the disease is characterized by the onset of se-
vere lameness and disintegration of the laminae, which
connect the hoof wall to the underlying dermis and third
phalanx [3]. In many cases, the pathology progresses
until the weight of the horse causes dorsopalmar rota-
tion of the third phalanx, detaching it from the hoof
wall. This condition is usually not reversible and euthan-
asia is often the only humane option. In many instances,
horses that survive an episode of acute laminitis are
crippled for life. This stage of the disease is termed* Correspondence: bchowdhary@cvm.tamu.edu
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distribution, and reproduction in any mediumchronic laminitis or “founder”. Acute laminitis transi-
tions to the chronic form of the disease in an estimated
75% of cases [4], leaving the majority of afflicted horses
permanently lame.
Despite intense efforts to understand the root cause of
acute laminitis, much less attention has been focused on
the pathophysiology of chronic laminitis. A handful of
studies have investigated changes in laminar morph-
ology, metabolism, and gene expression in foundered
horses [5-8], although several recent studies have fo-
cused on the efficacy of different management strategies
to ameliorate pain and improve quality of life [9,10]. Lit-
tle is known, therefore, about how chronic foot pain and
inflammation affect the horse on a global level. A recent
study quantified behavioral changes indicative of pain in
horses with chronic laminitis; these changes were asso-
ciated with alterations in morphology and gene expres-
sion of the lateral digital nerve and dorsal root ganglia
that are consistent with neuropathic pain, suggestingoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Image of the master DIGE gel stained with Deep
Purple showing equine plasma depleted of albumin and IgG.
The location of each of the ten spots chosen for identification with
LC-MS/MS is labelled with the corresponding spot number.
Table 1 Fold changes and P values of spots selected for
protein identification
Spot # Fold Change P value
457 −1.26 0.027
462 −1.2 0.005
819 −1.3 0.031
836 −1.75 0.043
980 1.49 0.036
1056 −1.37 0.028
1057 −1.34 0.021
1083 −1.67 0.036
1272 −2.11 0.002
1299 2.26 0.006
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results from peripheral nerve damage outside of the foot
[11]. In addition, Wagner et al. found that horses with
chronic laminitis show excessive dermal inflammatory
responses to a panel of allergens [12], suggesting an in-
appropriate activation of the systemic immune response.
To our knowledge, however, these studies are the only
published reports describing basic scientific investiga-
tions of chronic laminitis.
The dearth of information regarding how chronic lam-
inar inflammation affects the horse as a whole is a major
obstacle to understanding why certain horses experience
recurrent bouts of laminitis and how these bouts can be
prevented. As a first step towards characterizing global
alterations in the physiology of horses with chronic
laminitis, we used DIGE followed by LC-MS/MS to de-
tect differentially expressed plasma proteins in foun-
dered horses. Plasma was chosen as the sample matrix
because the blood is a primary means of transport for
numerous effector hormones and cytokines of the im-
mune and endocrine systems, which have been sug-
gested to be altered in chronic laminitis [12,13].
Results
Population characteristics
The control (CON) and laminitis (LMN) groups were
balanced for age and gender. None of the horses in the
CON group exhibited signs of lameness at the time of
sample collection. Three of the four horses in the LMN
group were persistently lame; the fourth experienced
intermittent lameness but was sound on the day of sam-
ple collection. Two of the permanently lame horses were
being treated with a low level of phenylbutazone (1 g
per day), a non-steroidal anti-inflammatory drug com-
monly used in veterinary practice. Horses in both groups
were in good body condition and did not exhibit any evi-
dence of injury or illness other than laminitis. White
blood cell counts obtained on the same day that plasma
was collected for DIGE were within normal parameters
and did not differ between groups (P = 0.46).
Detection of differentially expressed spots
In order to view global changes in the plasma of horses
with chronic laminitis, we performed DIGE on plasma
depleted of albumin and IgG. The Decyder software
detected ~2500 individual spots, 42 of which were differ-
entially expressed in the LMN group as compared to
controls (P < 0.05). Manual inspection of the spot histo-
grams in the DIA module revealed that 32 of the 42
spots were most likely artefacts based on the size and
shape of the 3D intensity profile. Ten spots (maximum
slope < 2.5, area > 300 pixels, and maximum volume >
100,000 pixels) were chosen for identification using LC-
MS/MS (Figure 1 and Table 1). Table 1 describes therelative fold change in intensity and associated P value
for each of the 10 spots. We found no evidence to sug-
gest that the horse in the LMN group that was not lame
at the time of sampling differed from the other horses in
the group or was a possible outlier. In addition, no dif-
ferences were noted between the two horses treated with
phenylbutazone and those that were unmedicated.
Protein identification
Twenty one proteins were identified from the LC-MS/
MS data generated from the 10 digested spots (Table 2).
Human keratin and trypsin derivatives were assumed to
be contaminants (trypsin was used as a digestion enzyme
prior to LC-MS/MS) and not included in the final list of
differentially expressed proteins. Likewise, although the
majority of plasma albumin was depleted during sample
preparation, it was identified in one of the differentially
expressed spots but was not included in Table 2. Pro-
teins identified from spots upregulated in LMN horses
Table 2 Names and NCBI accession numbers of proteins identified in differentially expressed spots
DIGE
Spot #
Protein name Accession
number (NCBI)
MW
(kDa)
Sequence
coverage (%)
No.
peptides
Upregulated
980 PREDICTED: similar to angiotensinogen [Equus caballus] gi|194206059 70 3.12% 2
980 PREDICTED: alpha-2-macroglobulin isoform 3 [Macaca mulatta] gi|109095556 161 1.31% 2
980 PREDICTED: similar to antithrombin protein [Equus caballus] gi|149708147 52 5.40% 3
1299 PREDICTED: apolipoprotein A-IV [Equus caballus] gi|149716543 43 6.82% 3
1299 PREDICTED: similar to Complement C3 precursor [Equus caballus] gi|194212541 186 2.05% 4
Dowregulated
457 PREDICTED: similar to alpha-1-antitrypsin; serine protease inhibitor [Equus
caballus]
gi|194225326 47 13.30% 5
457 PREDICTED: similar to Alpha-2-HS-glycoprotein precursor (Fetuin-A) [Equus
caballus]
gi|194222675 39 10.20% 3
457 alpha-1-antitrypsin [Equus caballus] gi|197631767 47 11.90% 6
462 PREDICTED: similar to Plasma protease C1 inhibitor precursor (C1 Inh) (C1-
inhibiting factor) [Equus caballus]
gi|149758084 53 9.24% 5
819 PREDICTED: similar to Vitronectin precursor (S-protein) (V75) [Equus caballus] gi|194217342 55 3.51% 2
819 PREDICTED: similar to Plasma protease C1 inhibitor precursor (C1 Inh) (C1-
inhibiting factor) [Equus caballus]
gi|149758084 53 5.88% 3
819 PREDICTED: kininogen 1 [Equus caballus] gi|149731462 58 5.83% 3
836 PREDICTED: similar to Fibrinogen gamma chain [Equus caballus] gi|194208381 52 4.20% 2
836 immunoglobulin alpha constant heavy chain [Equus caballus] gi|32331167 37 5.83% 2
836 PREDICTED: similar to antithrombin protein [Equus caballus] gi|149708147 52 19.40% 8
1056 Immunoglobulin mu heavy chain constant chain secreted form gi|51831151 50 4.43% 2
1056 PREDICTED: similar to Fetuin-B precursor (Gugu) [Equus caballus] gi|149731458 42 7.59% 3
1056 PREDICTED: similar to Fibrinogen gamma chain [Equus caballus] gi|194208381 52 11.70% 7
1057 PREDICTED: similar to Fetuin-B precursor (Gugu) [Equus caballus] gi|149731458 42 8.12% 3
1057 PREDICTED: similar to Fibrinogen gamma chain [Equus caballus] gi|194208381 52 11.30% 5
1083 PREDICTED: similar to Alpha-2-antiplasmin precursor (Alpha-2-plasmin
inhibitor) [Equus caballus]
gi|149724158 55 8.96% 4
1083 PREDICTED: similar to Fibrinogen gamma chain [Equus caballus] gi|194208381 52 7.08% 3
1083 PREDICTED: similar to Fetuin-B precursor (Gugu) [Equus caballus] gi|149731458 42 17.00% 6
1272 PREDICTED: similar to coagulation factor X protein [Equus caballus] gi|194222063 54 5.77% 3
1272 PREDICTED: similar to Complement C3 precursor [Equus caballus] gi|194212541 186 1.99% 3
Predicted molecular weight of each protein, the number of peptides identified from each protein, and the percentage of the total sequence covered by the
identified peptides are also shown.
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apolipoprotein A-IV; these are presented at the top of
Table 2. Antithrombin and complement factor C3 pre-
cursor were identified in both up- and down-regulated
spots. The remainder of the differentially expressed pro-
teins were from spots downregulated in the LMN group.
Annotation and ontology
The horse genome, though sequenced, is only partially
annotated. Therefore, the human orthologs were used to
identify gene function and overrepresented gene ontolo-
gies among differentially expressed proteins (Table 3).
Five of the proteins identified by MS were found inmultiple spots and one protein showed differential ex-
pression of two of its subunits (fibrinogen beta and
gamma chains). Therefore, of the 21 proteins, only 16
were unique. All 16 proteins belonged to the extracellu-
lar compartment or were secretory molecules stored
within platelet alpha granules. Molecular functions of
the proteins were predominated by serine endopeptidase
inhibitory activity. Overrepresented biological process
ontologies included response to wounding, defense re-
sponse, coagulation, and inflammatory response. Eleven
of the 16 proteins were identified as being involved in
the inter-related coagulation, kininogen, and comple-
ment cascades. The remaining proteins included alpha-
Table 3 Gene ontologies of the human orthologs of differentially expressed equine plasma proteins
Spot Gene Name Expression Molecular Function KEGG Pathway
980 alpha-2-
macroglobulin
Up-regulated Serine-type endopeptidase inhibitor activity, growth factor binding,
cytokine binding, chemokine binding
Complement and
coagulation
cascades
980 angiotensinogen Up-regulated Serine-type endopeptidase inhibitor activity, growth factor activity,
acetyltransferase activator activity, angiotensin receptor binding
Renin-angiotensin
system
1299 apolipoprotein A-
IV
Up-regulated Phospholipid binding, antioxidant activity, cholesterol transporter
activity
1272 coagulation factor
X
Down-regulated Serine-type endopeptidase activity Complement and
coagulation
cascades
836 fibrinogen beta
chain
Down-regulated Protein binding, bridging Complement and
coagulation
cascades
1056,
1057,
1083
fibrinogen gamma
chain
Down-regulated Protein binding, bridging Complement and
coagulation
cascades
836 IgM Down-regulated Antigen binding
1056 IgA Down-regulated Antigen binding
819 kininogen 1 Down-regulated Pattern binding, cysteine-type endopeptidase inhibitor activity,
heparin binding
Complement and
coagulation
cascades
819 protein S, alpha
(vitronectin)
Down-regulated Endopeptidase inhibitor activity, calcium ion binding Complement and
coagulation
cascades
457 alpha-1 antitrypsin Down-regulated Serine-type endopeptidase inhibitor activity Complement and
coagulation
cascades
836, 980 antithrombin Down-regulated (836),
Up-regulated (980)
Pattern binding, serine-type endopeptidase inhibitor activity, heparin
binding
Complement and
coagulation
cascades
1083 alpha-2
antiplasmin
Down-regulated Serine-type endopeptidase inhibitor activity Complement and
coagulation
cascades
462, 819 C1 inhibitor Down-regulated Complement binding, serine-type endopeptidase inhibitor activity Complement and
coagulation
cascades
457 alpha-2-HS-
glycoprotein
Down-regulated Cysteine-type endopeptidase inhibitor activity, protein tyrosine
kinase inhibitor activity
1056,
1057,
1083
fetuin B Down-regulated Cysteine-type endopeptidase inhibitor activity
1272,
1299
similar to
Complement C3
precursor
Down-regulated
(1272), Up-regulated
(1299)
Endopeptidase inhibitor activity Complement and
coagulation
cascades
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lar chaperones and participants in the acute phase re-
sponse [14,15], the immunoglobulin heavy chains alpha
and mu (IgA and IgM), and apolipoprotein A-IV (APO
AIV), which is an anti-inflammatory molecule [16].
Immunoglobulin concentrations
The differences in IgA and IgM concentrations sug-
gested by DIGE were not confirmed by ELISA. IgA con-
centrations were similar between CON and LMN groups(266 ± 44 mg/dL LMN vs. 254 ± 44 mg/dL CON,
P = 0.45), as were IgM concentrations (107 ± 11 mg/dL
LMN vs. 115 ± 7 mg/ml CON, P = 0.27).
Coagulation panel
Because the majority of differentially expressed proteins
were involved in the coagulation cascade, we assessed
the physiological relevance of our DIGE results by test-
ing coagulation parameters in seven LMN horses: an-
other three horses with chronic laminitis were used in
Figure 2 Western blot and densitometry quantification of
bands shows a significant (P < 0.05) elevation of apolipoprotein
A-IV in horses with chronic laminitis (LMN) as compared to
normal controls (CON).
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ment. Five of the seven horses, including three of the
four used for the DIGE study, had prolonged prothrom-
bin times (PT, Table 4), indicating that the LMN group
was statistically different from the reference population
(P < 0.01). It should be noted that none of the animals in
the LMN group had a history of coagulopathy. Fibrino-
gen concentration derived from prothrombin time was
elevated in six of seven animals, including all four horses
used for the DIGE experiment, although this finding was
not corroborated by the more accurate Clauss method
of fibrinogen quantification. Fibrin D-dimer was elevated
in only one animal.
APOA-IV concentration
Immunoblotting for equine APOA-IV using an anti-
human antibody was successful, with a single band
detected at ~30 kDa. No other bands were detected on
the blot [17]. Densitometry showed a significant
(P < 0.05) elevation of APOA-IV in horses with chronic
laminitis (Figure 2).
Discussion
The data presented herein describe, for the first time,
plasma proteome changes in chronic equine laminitis.
Our results suggest that a number of proteins involved
in immune regulation are differentially expressed in
horses with chronic equine laminitis. In particular, the
anti-inflammatory protein APOA-IV was elevated ap-
proximately two-fold in foundered horses. Although no
major deficits in the coagulation cascade were seen in
the present study, possible alterations in the comple-
ment and kininogen cascades have yet to be explored.
Our results suggest that chronic inflammation of the
laminae of the hoof might be associated with system-
wide changes in immune function and that this hypoth-
esis warrants further investigation. These conclusions
are discussed in detail below.Table 4 Coagulation indices in horses with chronic
laminitis
Horse ID PT PTT AT Fib PT Fib Clauss D dimer
L1 10.8 44.2 258 538* 232 618*
L2 11.3* 48.9 222 580* 209 211
L3 11.5* 46.3 216 543* 199 212
L4 11.0 34.0* 238 378 168 261
L5 11.6* 49.6 228 452* 195 497
L7 11.5* 45.3 206 783* 311* 238
L8 11.3* 42.9 226 396* 184 413
Normal clinical reference ranges are as follows: PT: prothrombin time, 9.7 –
11.2 s. PTT: partial thromboplastin time, 39.3 – 56.1 sec. AT: antithrombin
activity, >130 % NHP. Fib PT: fibrinogen (PT method), 207–386 mg/dL. Fib
Clauss: fibrinogen (Clauss method), 96–271 mg/dL. D dimer: D dimer of fibrin,
111 – 612 ng/ml. Asterisks indicate deviation from normal reference range.Technological considerations
DIGE has been used successfully to identify contributing
factors and biomarkers of a number of human diseases,
including multiple sclerosis [18], acute and chronic liver
disease [19,20], and various cancers [21-25]. To our
knowledge, however, DIGE has only been applied to
horses in two previous studies; these authors used DIGE
with and without depletion of abundant serum proteins
to investigate equine recurrent uveitis (ERU) [26,27], a
chronic inflammatory disorder of the eye with many
similarities to human autoimmune uveitis. As in our
study, antibodies directed against human proteins
removed a large portion of abundant equine serum pro-
teins, including albumin and IgG [27]. Zipplies et al.
identified kininogen, apolipoprotein A-IV, IgM, and
alpha-2-HS glycoprotein as differentially expressed in
ERU [27]; the overlap between their results and ours
may be because ERU and chronic laminitis are both
chronic inflammatory diseases and similar pathways are
likely involved in disease pathogenesis. It must be noted,
however, that the direction of change seen in APOA-IV
and kininogen in the present study was not consistent
with that seen by Zipplies et al., although the reason for
this remains unknown.
Of the 16 differentially expressed proteins identified in
this study, 14 have already been associated with other
chronic diseases in rats [28], humans [18-22,24,29,30],
and horses [26] using DIGE. To our knowledge, coagula-
tion factor X and IgA have not been associated with ei-
ther acute or chronic diseases using DIGE based
proteomics. The high level of redundancy in differen-
tially expressed proteins among various disease states
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detecting relatively high abundance proteins. Alterna-
tively, there could be a core group of proteins that are
differentially expressed during chronic inflammation.
Analogous to the “acute phase reactants” seen during
acute trauma, infection, or stress, these “chronic phase
reactants” might serve a similar purpose in modulation
of the immune response. Further standardization of ex-
perimental proteomics methods and meta-analysis of a
larger number of studies is necessary to confirm or re-
fute this hypothesis.
Coagulation and complement
In our study, the majority (11 of 16) of differentially
expressed proteins belonged to the inter-related coagula-
tion, complement, and kininogen cascades. The coagula-
tion cascade in LMN horses was characterized by the
decreased expression of clotting factors such as factor X
and fibrinogen and the increased expression of the in-
hibitor antithrombin, all of which would inhibit clotting.
This was balanced, however, by an increase in alpha-2-
macroglobulin and a decrease in protein S; the effect of
these two changes would be to promote clotting through
the inhibition of the anti-coagulant protein C. Changes
in abundance of liver-associated clotting proteins are
dependent upon the rates of both production and con-
sumption, so the DIGE results provided limited informa-
tion about the ability of the blood to clot. We therefore
assessed the functional significance of our results using a
coagulation panel, which showed a slightly prolonged
prothrombin (PT) time. It should be noted that, even
though PT time was elevated above normal levels in 5
horses, the clinical relevance of this finding is yet to cor-
roborated by other approaches. Findings from the co-
agulation panel were sufficient to rule out the presence
of major coagulopathies such as disseminated intravas-
cular coagulation and antithrombin deficiency, but un-
fortunately do not provide insight as to the mechanism
underlying the changes in clotting proteins seen with
DIGE. One possible explanation for the alteration in
liver-associated proteins is the over-expression of
interleukin-1 (IL-1) by white blood cells of horses with
chronic laminitis (S. Steelman, unpublished observation).
IL-1 has the potential to both positively and negatively
regulate hepatocyte expression of a number of acute
phase proteins [31]; specifically, it has been shown to in-
duce expression of angiotensinogen and alpha-2-
macroglobulin [32,33], both of which were upregulated
in our study. Further investigation of this possibility is
currently underway in our laboratory.
As two of the horses in the LMN group were being
treated with the NSAID phenylbutazone at the time of
sample collection, this had the potential to influence our
results. Although, to the best of our knowledge,phenylbutazone use has not been proven to directly alter
the expression of any of the diffferentially expressed pro-
teins in the current study, we cannot rule out this possi-
bility. In addition, NSAIDs are known to affect the
coagulation cascade through their regulation of prosta-
glandins; however, we saw no obvious differences in any
of the clotting parameters tested in the two horses re-
ceiving treatment (L1 and L2) as compared with the rest
of the group. Indeed, previous reports suggest that
phenylbutazone at the dose used in the current study
had no effect on thrombus formation, fibrinogen con-
centration, or factor Xa activity in rats [34].
APOA-IV
Our results showed a significant upregulation of apoli-
poprotein A-IV in horses with chronic laminitis as com-
pared to controls. APOA-IV is an essential component
of chylomicrons and is produced by the small intestine,
particularly in response to the ingestion of triglycerides
[35]. In this way, it functions as a satiety factor [36], but
it is also known to have anti-oxidant [37] and anti-
inflammatory [38] properties. Vowinkel and colleagues
[38] showed that APOA-IV ameliorates experimentally-
induced colitis in mice by attenuating the upregulation
of P-selectin and decreasing microvascular adhesion of
platelets and leukocytes. Studies in horses and dogs have
shown extensive polymorphism of APOA-IV [17]; in
humans, certain alleles have been associated with ele-
vated blood glucose and triglyceride levels as well as
body mass index [16]. The tissue sources and physio-
logical functions of APOA-IV have yet to be explored in
horses. Evidence exists, however, that serum APOA-IV
levels are influenced by the gastrointestinal microflora in
mice [39], which, like horses, are hindgut fermenters.
Preliminary data from our laboratory suggest that the
composition of fecal microflora is altered in horses with
chronic laminitis as compared with controls, thus pro-
viding a possible explanation for the elevation of APOA-
IV seen in the present study. The underlying mechanism
is currently unknown, although the composition of the
hindgut microflora play an important role in the devel-
opment of acute laminitis [40] and could possibly con-
tribute to exacerbation of symptoms in chronic laminitis
as well. Future studies will focus on these questions and
their relevance to the problem of equine laminitis.
Conclusions
Our results suggest that chronic equine laminitis is asso-
ciated with specific changes in the plasma proteome,
which might be reflective of alterations in the immune
system that are not confined to the foot. Specifically, the
altered abundance of complement proteins and acute
phase reactants suggests a chronic activation of the in-
nate immune response. Our results provide a base upon
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attenuating inflammation and reducing the pain asso-
ciated with this devastating disease.
Methods
Animals and sample collection
Blood samples were collected from horses residing at
the Hoof Diagnostic and Rehabilitation Clinic (Bryan,
TX) in accordance with the Texas A&M University Col-
lege of Veterinary Medicine guidelines regarding re-
search performed on non university-owned animals. All
animal protocols were approved by the Texas A&M Uni-
versity College of Veterinary Medicine Clinical Research
Review Committee (CRRC# 10–52) and were performed
with the consent of the owner or the owner’s agent.
Horses were diagnosed as having chronic laminitis
(LMN, n = 4) by a licensed veterinarian based on clinical
presentation, case history, and radiographic evidence of
dorsopalmar rotation of the distal phalanx. Horses in the
control group (CON, n = 4) were housed either at the
clinic or at a nearby farm and had no history of lamin-
itis. Both groups of horses, CON and LMN, were 15 to
20 years of age. Please see Additional file 1 for detailed
descriptions of each animal used in the study.
Blood samples were collected from the jugular vein
into evacuated blood tubes containing either heparin or
sodium citrate. Tubes were inverted a minimum of eight
times to ensure adequate mixing of the anticoagulant.
Heparinized samples were centrifuged at 1200 x g and
plasma was harvested and stored at −80°C. No protease
inhibitors were added to the samples. Citrated samples
were immediately transported to the Texas A&M Col-
lege of Veterinary Medicine Clinical Pathology Labora-
tory for evaluation of coagulation parameters. All
samples were collected between 9:00 and 11:00 am.
Sample preparation for DIGE
All sample preparation and DIGE experiments were
conducted at the Texas A&M University Protein Chem-
istry Laboratory. Details of the DIGE methods used have
been described previously [41]. Frozen plasma (CON,
n = 4; LMN, n = 4) was depleted of albumin and IgG
using human-specific affinity chromatography columns
(Seppro, Sigma-Aldrich, St. Louis, MO) to enrich sam-
ples for low-abundance proteins. Human affinity chro-
matography reagents have been used successfully in
horses for depletion of serum proteins [27]. A reference
sample (containing equal amounts of protein from each
of the 4 CON and 4 LMN samples) was used as a inter-
gel standard. Forty-five micrograms of each CON and
LMN sample was labeled with 200 pM Cy3 or Cy5 dye
in a balanced design to reduce potential effects of dye
bias; the reference sample was labeled with 200 pM Cy2.
Equal amounts of paired LMN and CON samples, plusthe reference sample, were mixed and loaded onto an
isoelectric focusing strip (DryStrip, 24 cm, pH 4–7, GE
Healthcare). Proteins were focused at 50 μA per strip for
a total of 50,200 Vh and then separated on 12% SDS-
PAGE gels. A total of four gels were used, with each gel
containing equal amounts of protein from one CON
sample, one LMN sample, and the reference sample.
Gel imaging and DeCyder analysis
Gels were scanned on a Typhoon Trio fluorescent
imager (GE Healthcare) with an image resolution of
100 μm. The Biological Variation Analysis (BVA) and
the Batch Processor modules of the DeCyder v6.5 soft-
ware package were used to identify protein spots in each
gel, to quantify fluorescent intensity of the spots, and to
perform statistics. Criteria for signficantly differentially
expressed spots included identification on at least three
of the four gels and a P value < 0.05 by Student’s inde-
pendent t test. Spots selected for identification by LC-
MS/MS were robotically picked (Ettan Spot Picker, GE
Healthcare) out of one gel, digested with trypsin, and
shipped to the University of Texas – San Antonio Pro-
teomics Core service lab for LC-MS/MS analysis.
Protein identification
MS/MS samples were analyzed using Mascot (Matrix
Science, London, UK; version Mascot) and X! Tandem
(The GPM, thegpm.org; version 2007.01.01.1). X! Tandem
and Mascot were set up to search the NCBI database
of nonredundant proteins (NCBInr_20091018.fasta,
9910686 entries) assuming the digestion enzyme trypsin.
Scaffold (version Scaffold_3_00_04, Proteome Software
Inc., Portland, OR) was used to validate MS/MS based
peptide and protein identifications. Peptide identifica-
tions were accepted if they could be established at
greater than 95.0% probability as specified by the Pep-
tide Prophet algorithm [42]. Protein identifications were
accepted if they could be established at greater than
99.0% probability and contained at least 2 identified
peptides. Protein probabilities were assigned by the Pro-
tein Prophet algorithm [43]. Mass spectra have been
deposited in the PRIDE database [44] under accession
number 22842.
Gene ontology
The horse genome, although sequenced, is partially
annotated; human orthologs of the equine proteins were
therefore used to search for significant gene ontologies.
Biological processes, molecular functions, cellular com-
ponents, and relevant pathways were identified using the
DAVID algorithm (v6.7, [45-47]). Significance was
judged by an adjusted P value less than 0.01 and a false
discovery rate of less than 5%.
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Capture ELISAs were performed to validate DIGE results
for selected proteins. Plasma concentrations of IgA and
IgM were determined using validated antibody pairs (Bethyl
Labs, Montgomery, TX) and standard protocols. Briefly,
high protein-binding 96 well plates (Nunc MaxiSorp,
Thermo Scientific, Rockford, IL) were coated with 100 μg
of unlabelled capture antibody overnight at 4°C. Plates
were blocked with SuperBlock buffer (Thermo Scien-
tific, Waltham, MA) for 30 min at room temperature.
Whole plasma samples were diluted 1:4,000 in assay buffer
(10% SuperBlock in PBS) and 100 μl of each diluted sam-
ple was pipetted in duplicate onto the plates, which were
then incubated at 37°C for 90 min. HRP-conjugated detec-
tion antibodies were diluted 1:50,000 (IgM) or 1:150,000
(IgA) in assay buffer and incubated on the plates for 2 h at
room temperature. SigmaFast OPD (Sigma, St. Louis MO)
was used as a substrate for HRP. Sample concentrations
were calculated using dilutions of a reference serum of
known concentration. Comparisons between groups were
made by Student’s t test using a variation of the S program-
ming language called R, which is commonly used for stat-
istical analysis (http://www.r-project.org). A P value< 0.05
was considered sufficient to reject the null hypothesis.
Coagulation panel
In order to explore potential physiological consequences
of differentially expressed proteins identified using DIGE,
a standard panel of coagulation tests was performed by
the Texas A&M College of Veterinary Medicine Clinical
Pathology Laboratory on the 4 LMN horses used for the
DIGE experiment plus an additional 3 LMN cases that
were available at the time of sample collection. None of
the CON horses were available for additional sample col-
lection at this time. Reported equine-specific reference
ranges are those used for clinical cases at the Texas A&M
Veterinary Medical Teaching Hospital. Comparisons be-
tween groups were performed by χ2 analysis using the R
programming language. A P value < 0.05 was considered
sufficient to reject the null hypothesis.
Western blot
Immunoblotting for APOA-IV was performed according
to standard protocols. NuPage equipment, gels, and buf-
fers (Invitrogen, Carlsbad, CA) were used for protein elec-
trophoresis and transfer according to the manufacturer’s
instructions. Briefly, 1 μl of plasma from each horse was
mixed with 10x NuPage Sample Buffer, NuPage Redu-
cing Agent, and 5.5 μl of water, heated to 70°C for
10 min, and separated by electrophoresis on 4-12% Bis-
Tris gradient gels. Gels were transferred to PVDF mem-
branes, which were then rinsed with distilled water and
blocked using 5% non-fat dried milk (NFDM) in a Tris-
buffered saline solution containing 0.05% Tween-20(TBST). Primary antibody (mouse anti-human APOA-
IV, Abcam, Cambridge, UK) was diluted 1:1,000 in
NFDM-TBST. Secondary antibody (goat anti-mouse
IgG – HRP conjugated, Abcam) was diluted 1:5,000 in
NFDM-TBST. Bound antibody was visualized by
addition of a chemiluminescent substrate (SuperSignal
West Dura ECL, Thermo Scientific) and blots were
imaged using a CCD camera system (Chemi-Doc, Bio-
Rad, Hercules, CA). Densitometry was performed using
Image J software [48]. Equal loading of all samples was
confirmed by staining of the membrane for total protein
using GelCode SafeBlue stain (Thermo Scientific). Com-
parisons between groups were made by Student’s t test.
Please see Additional file 2 for a detailed description of
the verification of antibody specificity and loading
controls.
Additional files
Additional file 1: Table S1. Details of individual animals used in the
study. CON: control, LMN: laminitis, DIGE: animal was included in the
DIGE proteomics experiment, COAG: animal was included in the
coagulation panel experiment, WB: animal was included in the APOA-IV
western blot experiment, G: gelding, M: mare, S: stallion, QH: Quarter
horse or Quarter horse-type, TB: Thoroughbred or Thoroughbred-type,
ARAB: Arabian, BCS: body condition score, ukn: unknown.
Additional file 2: Table S2. Equine proteins with similarity to human
APOA-IV as determined by the NCBI BLAST algorithm. Only proteins with
greater than 50% coverage are included. [49]
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